News

Early Oral Feeding Benefits Bowel Surgery Patients


 

FROM THE ANNUAL CLINICAL CONGRESS OF THE AMERICAN COLLEGE OF SURGEONS

CHICAGO – A total of 80% of bowel resection patients tolerated early fluids one day after surgery, based on data from 100 patients.

"Early oral feeding is an important part of fast-track surgery, which enhances recovery after surgery," but feeding in patients undergoing emergency bowel resection is often delayed until the resolution of ileus, Dr. Mohamed E. Shams of Suez Canal University in Ismailia, Egypt, said at the annual clinical congress of the American College of Surgeons.

Dr. Shams and colleagues randomized 100 adults who underwent small or large bowel resection into two groups. The early group comprised 50 patients who received fluid oral feedings on the first day after surgery. The late group comprised 50 patients who received oral feedings after the resolution of ileus.

Overall, 80% of patients in the early group tolerated the early oral feeding. In addition, patients in the early group averaged a significantly shorter time than did the late group to the passage of flatus (3.2 days vs. 0.8 days, respectively), and stool (4.4 days vs. 1.2 days, respectively).

Postoperative monitoring showed that the chest infections occurred in four patients in the early feeding group compared with 10 patients in the late feeding group, while wound infections occurred in 12 patients in the early group and 15 patients in the late group, Dr. Shams said. No incidents of a burst abdomen occurred in the early group, and three incidents occurred in the late group.

"Early oral feeding after emergency intestinal surgery is safe and well tolerated by the majority of patients, without an increase in mortality and morbidity risk," said Dr. Shams. "It also has a positive impact on reduction in hospital stay," he said.

The findings were limited by the small number of patients, but the results suggest that a majority of patients undergoing emergency intestinal surgery can benefit from early feeding, Dr. Shams noted.

Dr. Shams had no financial conflicts to disclose.

Recommended Reading

Noroviruses Affecting Diverse Populations
MDedge Internal Medicine
Two Drugs Not Better Than One for C. Difficile
MDedge Internal Medicine
FDA Approves Regorafenib for Metastatic Colorectal Cancer
MDedge Internal Medicine
Second TNF-Blocker Approved for Refractory Ulcerative Colitis
MDedge Internal Medicine
The Problem With PPIs
MDedge Internal Medicine
Rapid Tests Accurate in First-Line HCV Screening
MDedge Internal Medicine
Intestinal Liner Improves Glycemic Markers in Type 2 Diabetes
MDedge Internal Medicine
Screening All Colorectal Tumors Detects Lynch Syndrome Best
MDedge Internal Medicine
Panel Advises Approving Short Bowel Syndrome Drug
MDedge Internal Medicine
Less Liver Cancer in HCV Patients Given Antiviral Therapy
MDedge Internal Medicine